Panniculitis in Dermatomyositis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1+
SponsorUniversity Hospital, Strasbourg, France
About this trial
Adipose tissue involvement is rare in dermatomyositis. The occurrence of partial or diffuse lipodystrophy is a rare but well-characterized manifestation, particularly in juvenile forms of dermatomyositis. Panniculitis, on the other hand, is exceptional and rarely described in the literature, mostly in the form of clinical cases.
Panniculitis in dermatomyositis is exceptional. There are no validated diagnostic criteria or treatment recommendations. Treatment is based, by analogy, on the therapeutic strategy for lupus panniculitis and involves synthetic antimalarials combined with steroids and/or immunosuppressants.
The aim of this study is to describe panniculitis in dermatomyositis in order to determine whether there are clinical or histological characteristics that distinguish it from other causes of panniculitis, particularly panniculitis associated with lupus erythematosus.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subject aged 1 year and older
With a confirmed diagnosis of dermatomyositis
With a confirmed diagnosis of panniculitis
Disqualifiers
Panniculitis for which another cause has been established, particularly infectious and metabolic panniculitis
Trial population
Subject with a confirmed diagnosis of dermatomyositis and panniculitis
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Determine the clinical and histological characteristics of panniculitis in dermatomyositis
The investigators aim to describe: how inflammation of the subcutaneous fat manifests * in individuals with dermatomyositis * both: * clinically and visually in the patient * under the microscope (histology)
Time frame
Up to 30 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov